The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical Study
2015年11月10日 更新者:Xianglin Yuan、Huazhong University of Science and Technology
This prospective cohort study aims to observe the efficacy and safety of the first-line combined chemotherapy for advanced gastric cancer(AGC) in Chinese population.
研究概览
地位
未知
条件
详细说明
Establish a clinical database for the advanced gastric cancer patients treated with first-line combined chemotherapy in Tongji hospital.
1.1.Data including age, gender, smoking state, karnofsky performance score(KPS), disease history, clinical stage, primary tumor site, metastasis site, surgery, first-line chemotherapy, therapy after failure of first-line treatment, radiotherapy, toxicity, survival time, the time of free of progress, response were collected.
1.2.The peripheral blood samples were collected for further biomarker reserch.
- Kaplan-Meier and Cox model will be used to analyze the overall survival(OS) and progression-free survival(PFS) of advanced gastric cancer.
- Extract Deoxyribonucleic acid(DNA) from the the peripheral blood and research biomarkers related to the first-line combined chemotherapy for AGC.
研究类型
观察性的
注册 (预期的)
250
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Hubei
-
Wuhan、Hubei、中国、430030
- 招聘中
- Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
-
首席研究员:
- Xianglin Yuan, MD,PHD
-
接触:
- Xianglin Yuan, MD,PHD
- 电话号码:1 13667241722
- 邮箱:yxl@medmail.com.cn
-
接触:
- Suxian Wei, Master
- 电话号码:1 15927421058
- 邮箱:wsxattj@126.com
-
副研究员:
- Suxian Wei, MD
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 75年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
取样方法
概率样本
研究人群
Histopathology or cytopathology confirmed unresectable locally advanced, or recurrent, or metastatic chemotheapy-naive gastric cancer and gastroesophageal adenocarcinoma patients
描述
Inclusion Criteria:
- Histopathology or cytopathology proven gastric cancer or gastroesophageal adenocarcinoma;
- Unresectable locally advanced, or recurrent, or metastasis disease;
- Chemotherapy-naive or disease progress at least 6 months after adjuvant chemotherapy completed.
- Life expectancy of at least 3 months;
- ECOG score 0-2;
- Voluntarily signed the informed consent.
Exclusion criteria:
- Previously treated with first-line chemotherapy;
- First-line chemotherapy with single drug.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
Combined chemotherapy
AGC patients treated with first-line combined chemotherapy
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Overall survival(OS) . overall survival Overall survival(OS)
大体时间:From date of enrollment until the date of death from any cause, assessed up to 60 months
|
From date of enrollment until the date of death from any cause, assessed up to 60 months
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Progression-free survival(PFS)
大体时间:From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
|
From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
|
|
Objective response rate(ORR)
大体时间:The sum of complete remission (CR) rate and partial remission (PR) rate. Response will be measured through first-line treatment completion, up to 1 year
|
The sum of complete remission (CR) rate and partial remission (PR) rate. Response will be measured through first-line treatment completion, up to 1 year
|
|
Disease control rate(DCR)
大体时间:The sum of CR rate, PR rate and stable disease(SD) rate. Response will be measured through first-line treatment completion, up to 1 year
|
The sum of CR rate, PR rate and stable disease(SD) rate. Response will be measured through first-line treatment completion, up to 1 year
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
大体时间:Through first-line treatment completion,up to 24 weeks.
|
Through first-line treatment completion,up to 24 weeks.
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Xianglin Yuan, MD,PHD、Tongji Hospital
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2013年1月1日
初级完成 (预期的)
2016年6月1日
研究完成 (预期的)
2018年1月1日
研究注册日期
首次提交
2015年10月19日
首先提交符合 QC 标准的
2015年10月20日
首次发布 (估计)
2015年10月22日
研究记录更新
最后更新发布 (估计)
2015年11月11日
上次提交的符合 QC 标准的更新
2015年11月10日
最后验证
2015年10月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.